157 related articles for article (PubMed ID: 36218218)
21. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
Agostini C; Blau IW; Kimby E; Plesner T
Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
[TBL] [Abstract][Full Text] [Related]
22. Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey.
Wong J; Wood EM; Crispin P; Weinkove R; McQuilten ZK;
Intern Med J; 2019 Mar; 49(3):358-363. PubMed ID: 30129248
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
[TBL] [Abstract][Full Text] [Related]
24. Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.
Cinetto F; Francisco IE; Fenchel K; Scarpa R; Montefusco V; Pluta A; Wolf HM
Expert Rev Hematol; 2023 Apr; 16(4):237-243. PubMed ID: 37009667
[TBL] [Abstract][Full Text] [Related]
25. Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.
Edgar JDM; Richter AG; Huissoon AP; Kumararatne DS; Baxendale HE; Bethune CA; Garcez T; Misbah SA; Sorensen RU;
J Clin Immunol; 2018 Feb; 38(2):204-213. PubMed ID: 29423883
[TBL] [Abstract][Full Text] [Related]
26. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.
Wasserman RL
Allergy Asthma Proc; 2021 Nov; 42(6):489-494. PubMed ID: 34871156
[No Abstract] [Full Text] [Related]
28. Comparison of Weight-Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies.
Stump SE; Schepers AJ; Jones AR; Alexander MD; Auten JJ
Pharmacotherapy; 2017 Dec; 37(12):1530-1536. PubMed ID: 29028117
[TBL] [Abstract][Full Text] [Related]
29. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.
McQuilten ZK; Weinkove R; Thao LTP; Crispin P; Degelia A; Dendle C; Gilbertson M; Johnston A; Keegan A; Pepperell D; Pullon H; Reynolds J; van Tonder T; Trotman J; Waters N; Wellard C; Weston H; Morrissey CO; Wood EM
Blood Adv; 2024 Apr; 8(7):1787-1795. PubMed ID: 38592710
[TBL] [Abstract][Full Text] [Related]
30. Secondary immunodeficiency in lymphoproliferative malignancies.
Friman V; Winqvist O; Blimark C; Langerbeins P; Chapel H; Dhalla F
Hematol Oncol; 2016 Sep; 34(3):121-32. PubMed ID: 27402426
[TBL] [Abstract][Full Text] [Related]
31. Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases.
Ballow M; Sánchez-Ramón S; Walter JE
Front Immunol; 2022; 13():928062. PubMed ID: 35924244
[TBL] [Abstract][Full Text] [Related]
32. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus.
Jolles S; Michallet M; Agostini C; Albert MH; Edgar D; Ria R; Trentin L; Lévy V
Eur J Haematol; 2021 Apr; 106(4):439-449. PubMed ID: 33453130
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
34. Treatment of antibody immunodeficiency.
Litzman J
Vnitr Lek; 2019; 65(2):126-130. PubMed ID: 30909702
[TBL] [Abstract][Full Text] [Related]
35. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.
Reiser M; Borte M; Huscher D; Baumann U; Pittrow D; Sommer C; Stangel M; Fasshauer M; Gold R; Hensel M
Eur J Haematol; 2017 Aug; 99(2):169-177. PubMed ID: 28467615
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy.
Patel V; Cameron DW; Cowan J
Hematol Oncol; 2021 Oct; 39(4):584-588. PubMed ID: 34288002
[No Abstract] [Full Text] [Related]
37. Vaccines for prophylaxis of viral infections in patients with hematological malignancies.
Cheuk DK; Chiang AK; Lee TL; Chan GC; Ha SY
Cochrane Database Syst Rev; 2011 Mar; (3):CD006505. PubMed ID: 21412895
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency.
Joud Hajjar ; Nguyen AL; Constantine G; Kutac C; Syed MN; Orange JS; Sullivan KE
J Clin Immunol; 2020 Jan; 40(1):158-164. PubMed ID: 31758281
[TBL] [Abstract][Full Text] [Related]
39. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis.
Chai KL; Wong J; Weinkove R; Keegan A; Crispin P; Stanworth S; Morrissey CO; Wood EM; McQuilten ZK
Blood Adv; 2023 Jan; 7(1):20-31. PubMed ID: 35882473
[TBL] [Abstract][Full Text] [Related]
40. Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.
Soshnick SH; Joseph T; Bennett NJ
J Clin Immunol; 2021 Aug; 41(6):1208-1212. PubMed ID: 33740168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
